Chronic myeloid leukemia - some topical issues

被引：10

作者：

Mughal, T. ^{[1
]}

Cortes, J.

Cross, N. C. P.

Donato, N.

Hantschel, O.

Jabbour, E.

Kantarjian, H.

Melo, J. V.

Skorski, T.

Silver, R. T.

Goldman, J. M.

机构：

[1] Univ Texas, SW Med Ctr, Dept Hematol & Stem Cell Transplantat, Dallas, TX 75235 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[3] Univ Southampton, Wessex Reg Genet Lab, Salisbury, Wilts, England

[4] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA

[5] Austrian Acad Sci, Ctr Mol Med, A-1010 Vienna, Austria

[6] Hammersmith Hosp, Dept Haematol, Imperial Coll, London, England

[7] Temple Univ, Dept Microbiol & Immunol, Philadelphia, PA 19122 USA

[8] Cornell Univ, Weill Med Coll, Presbyterian Hosp, New York, NY USA

来源：

LEUKEMIA | 2007年 / 21卷 / 07期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL; IMATINIB MESYLATE; TYROSINE KINASE; BLAST CRISIS; RESISTANCE; CML; CELLS; INHIBITOR; FTY720;

D O I：

10.1038/sj.leu.2404733

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1347 / 1352

页数：6

共 44 条

[1] Allosteric inhibitors of Bcr-abl-dependent cell proliferation
Adrián, FJ
Ding, Q
Sim, TB
Velentza, A
Sloan, C
Liu, Y
Zhang, GB
Hur, W
Ding, S
Manley, P
Mestan, J
Fabbro, D
Gray, NS
[J]. NATURE CHEMICAL BIOLOGY, 2006, 2 (02) : 95 - 102
[2] Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABLM244V mutant allele
Anand, Mona
Khorashad, Jamshid
Marin, David
Apperley, Jane F.
Goldman, John M.
Kaeda, Jaspal Singh
[J]. BLOOD, 2006, 108 (08) : 2881 - 2882
[3] In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Ehab Atallah
Hagop Kantarjian
Jorge Cortes
[J]. Nature Medicine, 2007, 13 (1) : 14 - 14
[4] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Baccarani, Michele
Saglio, Giuseppe
Goldman, John
Hochhaus, Andreas
Simonsson, Bengt
Appelbaum, Frederick
Apperley, Jane
Cervantes, Francisco
Cortes, Jorge
Deininger, Michael
Gratwohl, Alois
Guilhot, Frangois
Horowitz, Mary
Hughes, Timothy
Kantarjian, Hagop
Larson, Richard
Niederwieser, Dielger
Silver, Richard
Hehlmann, Rudiger
[J]. BLOOD, 2006, 108 (06) : 1809 - 1820
[5] Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
Barnes, DJ
Palaiologou, D
Panousopoulou, E
Schultheis, B
Yong, ASM
Wong, A
Pattacini, L
Goldman, JM
Melo, JV
[J]. CANCER RESEARCH, 2005, 65 (19) : 8912 - 8919
[6] FTY720: Mechanism of action and potential benefit in organ transplantation
Brinkmann, V
[J]. YONSEI MEDICAL JOURNAL, 2004, 45 (06) : 991 - 997
[7] Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
Corbin, AS
La Rosée, P
Stoffregen, EP
Druker, BJ
Deininger, MW
[J]. BLOOD, 2003, 101 (11) : 4611 - 4614
[8] DanhauserRiedl S, 1996, CANCER RES, V56, P3589
[9] BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
Donato, NJ
Wu, JY
Stapley, J
Gallick, G
Lin, H
Arlinghaus, R
Talpaz, M
[J]. BLOOD, 2003, 101 (02) : 690 - 698
[10] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, Brian J.
Guilhot, Francois
O'Brien, Stephen G.
Gathmann, Insa
Kantarjian, Hagop
Gattermann, Norbert
Deininger, Michael W. N.
Silver, Richard T.
Goldman, John M.
Stone, Richard M.
Cervantes, Francisco
Hochhaus, Andreas
Powell, Bayard L.
Gabrilove, Janice L.
Rousselot, Philippe
Reiffers, Josy
Cornelissen, Jan J.
Hughes, Timothy
Agis, Hermine
Fischer, Thomas
Verhoef, Gregor
Shepherd, John
Saglio, Giuseppe
Gratwohl, Alois
Nielsen, Johan L.
Radich, Jerald P.
Simonsson, Bengt
Taylor, Kerry
Baccarani, Michele
So, Charlene
Letvak, Laurie
Larson, Richard A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) : 2408 - 2417

← 1 2 3 4 5 →